{
    "info": {
        "nct_id": "NCT04700124",
        "official_title": "A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)",
        "inclusion_criteria": "* Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%) urothelial histology.\n* Have clinically non-metastatic bladder cancer (N≤1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis\n* Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND)\n* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Has a known additional malignancy that is progressing or has required active anti-cancer treatment ≤3 years of study randomization with certain exceptions\n* Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)\n* Has ≥N2 disease or metastatic disease (M1) as identified by imaging\n* Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol\n* Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization or any radiotherapy to the bladder\n* Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC\n* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention\n* Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency virus (HIV) infection. Hepatitis B infection or known active Hepatitis C infection\n* Has a known psychiatric or substance abuse disorder\n* Has had an allogenic tissue/solid organ transplant\n* Has ongoing sensory or motor neuropathy Grade 2 or higher\n* Has active keratitis (superficial punctate keratitis) or corneal ulcerations\n* Has a history of uncontrolled diabetes defined as hemoglobin A1c (HbA1c) ≥8% or HbA1c 7% to <8% with associated diabetes symptoms",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%) urothelial histology.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC)",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histology"
                        },
                        {
                            "requirement_type": "disease type",
                            "expected_value": [
                                "urothelial carcinoma",
                                "muscle invasive bladder cancer"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "(T2-T4aN0M0 or T1-T4aN1M0)",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "T2-T4aN0M0",
                                "T1-T4aN1M0"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "predominant (≥50%) urothelial histology",
                    "criterion": "urothelial histology percentage",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have clinically non-metastatic bladder cancer (N≤1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis",
            "criterions": [
                {
                    "exact_snippets": "clinically non-metastatic bladder cancer (N≤1 M0)",
                    "criterion": "bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically non-metastatic bladder cancer (N≤1 M0)",
                    "criterion": "metastatic status",
                    "requirements": [
                        {
                            "requirement_type": "metastasis",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "(N≤1 M0)",
                    "criterion": "nodal status (N)",
                    "requirements": [
                        {
                            "requirement_type": "nodal involvement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N stage"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(N≤1 M0)",
                    "criterion": "distant metastasis (M)",
                    "requirements": [
                        {
                            "requirement_type": "distant metastasis",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "M stage"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis",
                    "criterion": "imaging assessment",
                    "requirements": [
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "computed tomography (CT)",
                                "magnetic resonance imaging (MRI)"
                            ]
                        },
                        {
                            "requirement_type": "imaging regions",
                            "expected_value": [
                                "chest",
                                "abdomen",
                                "pelvis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have adequate organ function.",
            "criterions": [
                {
                    "exact_snippets": "Have adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND)",
            "criterions": [
                {
                    "exact_snippets": "Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND)",
                    "criterion": "eligibility for Radical Cystectomy and Pelvic Lymph Node Dissection",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention",
                    "criterion": "live or live attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before first dose of study intervention"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has ongoing sensory or motor neuropathy Grade 2 or higher",
            "criterions": [
                {
                    "exact_snippets": "Has ongoing sensory or motor neuropathy Grade 2 or higher",
                    "criterion": "sensory or motor neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has active keratitis (superficial punctate keratitis) or corneal ulcerations",
            "criterions": [
                {
                    "exact_snippets": "Has active keratitis (superficial punctate keratitis)",
                    "criterion": "active keratitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "corneal ulcerations",
                    "criterion": "corneal ulcerations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency virus (HIV) infection. Hepatitis B infection or known active Hepatitis C infection",
            "criterions": [
                {
                    "exact_snippets": "Has a diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has a known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis B infection",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active Hepatitis C infection",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known psychiatric or substance abuse disorder",
            "criterions": [
                {
                    "exact_snippets": "Has a known psychiatric ... disorder",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a known ... substance abuse disorder",
                    "criterion": "substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has ≥N2 disease or metastatic disease (M1) as identified by imaging",
            "criterions": [
                {
                    "exact_snippets": "Has ≥N2 disease",
                    "criterion": "N stage of disease",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic disease (M1)",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "M1"
                        }
                    ]
                },
                {
                    "exact_snippets": "as identified by imaging",
                    "criterion": "disease identification method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "imaging"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had an allogenic tissue/solid organ transplant",
            "criterions": [
                {
                    "exact_snippets": "Has had an allogenic tissue/solid organ transplant",
                    "criterion": "allogenic tissue/solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC",
            "criterions": [
                {
                    "exact_snippets": "Has undergone partial cystectomy of the bladder",
                    "criterion": "partial cystectomy of the bladder",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "to remove any NMIBC or MIBC",
                    "criterion": "removal of NMIBC or MIBC",
                    "requirements": [
                        {
                            "requirement_type": "indication for cystectomy",
                            "expected_value": [
                                "NMIBC",
                                "MIBC"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol",
            "criterions": [
                {
                    "exact_snippets": "Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol",
                    "criterion": "cisplatin eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": "ineligible (as per protocol-defined cisplatin ineligibility criteria)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization or any radiotherapy to the bladder",
            "criterions": [
                {
                    "exact_snippets": "Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization",
                    "criterion": "prior systemic anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": [
                                "systemic anticancer therapy",
                                "investigational agents"
                            ]
                        },
                        {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any radiotherapy to the bladder",
                    "criterion": "radiotherapy to the bladder",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": "radiotherapy"
                        },
                        {
                            "requirement_type": "therapy site",
                            "expected_value": "bladder"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known additional malignancy that is progressing or has required active anti-cancer treatment ≤3 years of study randomization with certain exceptions",
            "criterions": [
                {
                    "exact_snippets": "Has a known additional malignancy",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is progressing",
                    "criterion": "additional malignancy progression",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "progressing"
                        }
                    ]
                },
                {
                    "exact_snippets": "has required active anti-cancer treatment ≤3 years of study randomization",
                    "criterion": "additional malignancy treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of uncontrolled diabetes defined as hemoglobin A1c (HbA1c) ≥8% or HbA1c 7% to <8% with associated diabetes symptoms",
            "criterions": [
                {
                    "exact_snippets": "history of uncontrolled diabetes",
                    "criterion": "uncontrolled diabetes",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin A1c (HbA1c) ≥8%",
                    "criterion": "hemoglobin A1c (HbA1c)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "HbA1c 7% to <8% with associated diabetes symptoms",
                    "criterion": "hemoglobin A1c (HbA1c)",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 7,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 8,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "HbA1c 7% to <8% with associated diabetes symptoms",
                    "criterion": "diabetes symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)",
            "criterions": [
                {
                    "exact_snippets": "Has received any prior systemic treatment for MIBC",
                    "criterion": "prior systemic treatment for MIBC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior systemic treatment for ... non-invasive muscle bladder cancer (NMIBC)",
                    "criterion": "prior systemic treatment for NMIBC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted",
                    "criterion": "prior treatment for NMIBC with intravesical BCG/chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)",
                    "criterion": "prior therapy with immune checkpoint inhibitors (PD-1, PD-L1/L2, CTLA-4)",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}